BEAM vs KNSA: which is the better buy in 2026?
Beam Therapeutics
NASDAQ:BEAM
Beam's base editing platform is approaching its first real clinical readouts with enough cash to get there, and the market still prices it like science fiction.
Full BEAM analysisKiniksa Pharmaceuticals International, plc
NASDAQ:KNSA
A one-drug company quietly becoming a two-drug franchise, with the second drug potentially bigger than the first.
Full KNSA analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is BEAM or KNSA the better buy in 2026?
BEAM and KNSA are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.
How does Alexandria compare BEAM and KNSA?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.